Please login to the form below

Not currently logged in
Email:
Password:

Merz acquire BioForm Medical

Merz Pharma have agreed to acquire BioForm Medical for $253m, expanding its presence in cosmetic pharmaceuticals

Merz Pharma Group have agreed to acquire BioForm Medical Inc (BFRM) for $253m, expanding its cosmetic pharmaceuticals portfolio. The privately held German pharmaceutical company already has a presence in anti-ageing skincare with their product Belotero - the world's first monophasic hyaluronic acid dermal filler with patented CPM technology.

Merz will pay $5.45 per BioForm share, a 60 per cent premium to the company's Thursday closing price.

BioForm, which went public in late 2007, specialises in injectable drugs to improve the appearance of the skin, including treatment of wrinkles and folds, as well as varicose veins. The company is non profitable, though sales have been improving and last November BioForm narrowed its loss forecast for its fiscal year ending June 30.

6th January 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...